Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.

Rapid Diagnostic Tests Compared for Invasive Amoebiasis

By Labmedica International staff writers
Posted on 30 Oct 2013
Image: Bichrolatex-Amibe colored latex slide agglutination test for extra-intestinal amoebiasis serodiagnosis (Photo courtesy of Fumouze Diagnostic).
Image: Bichrolatex-Amibe colored latex slide agglutination test for extra-intestinal amoebiasis serodiagnosis (Photo courtesy of Fumouze Diagnostic).
Three rapid immunoassays have been compared and evaluated for the diagnosis of invasive amoebiasis in an emergency department.

Sensitive rapid diagnostic tests (RDT) contribute to an early diagnosis and thus improve the prognosis. The test should be also specific to distinguish amoebic and pyogenic abscess in order to avoid a percutaneous drainage for diagnostic purposes and a broad-spectrum antibiotherapy.

Scientists at the Military Teaching Hospital (HIA) Bégin (Saint-Mandé, France) carried out a retrospective biological records review that included 639 patients for whom three serological tests were performed. They compared a latex agglutination test (LAT) with enzyme-linked immunosorbent assay and indirect hemagglutination assay in the diagnosis of invasive amoebiasis (IA) performed from January 1, 2001, to July 1, 2012.

The three different techniques performed for each patient at laboratory of Bégin Hospital were: a latex agglutination slide test (LAT) (Bichrolatex-Amibe, Fumouze Diagnostic; Levallois-Perret, France); an enzyme linked immunosorbent assay (ELISA) (NovaTec Entamoeba histolytica IgG-ELISA, DiaSorin SPA; Saluggia, Italy); and the Fumouze Diagnostic’s indirect hemagglutination assay Amibiase HAI (IHA).

A total of 639 patients with a performed serology were included and among them 75 had at least one positive serological result. Of these 75 patients, 46 had a final diagnosis of IA, 43 with hepatic amoebiasis, two with intestinal amoebomas and one with pleuropulmonary amoebiasis and 29 patients had another final diagnosis. The LAT was statistically more sensitive than ELISA and IHA.

The authors concluded that LAT could be used in any routine clinical laboratory because it is simple to perform and does not require any special equipment. The result is achieved quickly in 15 minutes. The interpretation is easy because the bicolored positive pattern is very distinguishable from a negative brown spot. The cost remains low at approximately EUR 5.22 per test in France. The LAT is a useful screening technique in the rapid diagnosis and the management of patients with febrile hepatalgia in emergency units. However, this test should be systematically confirmed by reference techniques (ELISA, IHA). The study was published on October 11, 2013, in the journal Diagnostic Microbiology and Infectious Disease.

Related Links:

Military Teaching Hospital Bégin
Fumouze Diagnostic 
DiaSorin SPA 



DIASYS DIAGNOSTIC SYSTEMS
KARL HECHT GMBH & CO KG
Dubai Bio Expo-2015

Channels

Genetic Tests

view channel
Image: The final result of a DNA sequencing process, with each color representing one of the four base chemicals, adenine, guanine, cytosine and thymine, that comprise DNA (Photo courtesy of Gerald Barber).

Gene Sequencing Reference Standard Increases Accuracy for Medical Laboratories

To reduce the variability in genetic test results that has been observed across different clinical laboratories and pathology groups, a new standard DNA reference has been introduced, which will improve... Read more

Hematology

view channel
Image: Immunochemistry of bone marrow biopsy from an acute myeloid leukemia patient showing sheets of CD34 positive cells; corresponding bone marrow aspirate showed only 20% blasts (Photo courtesy of All India Institute of Medical Sciences).

Immunohistochemistry Assesses Early Response in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a heterogeneous disease with respect to prognosis and early response assessment has an established role as predictor of remission rate, and overall and disease-free survival.... Read more

Industry News

view channel

Partners to Develop and Commercialize Noninvasive Tests for Bladder Cancer

An agreement between a major European university medical center and a multinational biotechnology company was designed to promote commercialization and further development of a liquid biopsy test for the diagnosis of bladder cancer. The liquid biopsy test is based on bladder cancer DNA methylation biomarkers developed... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.